In a blast from the past, COVID-19 vaccine developer Moderna (NASDAQ: MRNA) just made headlines in 2026. Shares jumped up ...

Initiate Moderna with a Hold rating at a $25 target price (lower than the current price), citing balanced risk-reward despite the advanced mRNA platform and robust pipeline. MRNA's near-term execution ...

WASHINGTON, DC: Jayanta Bhattacharya, Director of the National Institutes of Health. (Photo by Andrew Harnik/Getty Images) Director of the National Institutes of Health, Jay Bhattacharya, recently ...

STONY BROOK, NY / ACCESSWIRE / November 9, 2023 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced that it has ...

NEW ALBANY, OH / ACCESSWIRE / April 16, 2024 / AmplifyBio, a Contract Development and Manufacturing Organization (CDMO) and Contract Research Organization (CRO) focused on differentiating services ...

STONY BROOK, NY / ACCESSWIRE / July 13, 2023 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced that it has acquired ...

Cells use mRNA to build proteins, and after years of research, scientists learned how to harness this molecule to develop effective, safe and quick-to-make vaccines. Since the advent of this Nobel ...

Imagine dedicating your life to science, only to see your work undermined by conspiracy theories and political noise. Case in point: the Trump administration recently canceled over $766 million in ...

We asked experts about how the technology works, its safety and its potential in medicine. By Nina Agrawal Health Secretary Robert F. Kennedy Jr. has repeatedly questioned the safety of mRNA vaccines ...